Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camostat in Early COVID-19
NCT04455815Phase 2Terminated
- Sponsor
- Cancer Research UK
- Start
- Sep 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camostat mesilate in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Cancer Research UK. Primary endpoints: Number of Camostat Related Adverse Events and Serious Adverse Events at 28 days and Number of Adverse Events by Severity Grade at 28 days. Started Sep 2020; status: terminated.
02
Drugs
camostat mesilate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04455815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04455815.